If you have been reading about ACTH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-22. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
=== Horses === Horses are branded with both the hot-iron and cryogenic techniques. Their brands most often denote ownership. Owners will generally create a unique brand to identify the horses that belong to a given ranch. Freeze brands can also be used to denote a breed in general or to identify an animal with a specific breed registry. The brand is typically placed on a horse's haunches or its neck, near the crest.
== Research directions == Key research questions in PMOS focus on the best way to manage the condition, including with new anti-obesity drugs. In terms of criteria for diagnosis, age-specific levels of AMH need to be specified. Biomarkers are needed for early diagnosis and to guide drug development. Another open question is how to define the male phenotype to assess male relatives of women with PMOS. Research is exploring better ways to assess and predict metabolic complications. Current clinical tests for insulin resistance lack accuracy and standardisation, and the gold-standard method is impractical in clinical settings. Emerging approaches include multiomics, which may uncover biomarkers for diagnosis and subtyping, and artificial intelligence (AI)-based methods, which can identify patterns in medical data and also classify patients into subgroups. Combining AI with omics might improve early diagnosis, risk prediction, personalised treatment, and long-term monitoring, though robust validation in large, diverse cohorts remains necessary. As of 2024, studies have successfully developed in vitro PMOS disease models through human embryonic stem cells (hESCs) and induced pluripotent stem cell technology (iPSC). Both can be derived from individuals with PMOS and can differentiate into various cell types. Using adult somatic cells, iPSCs can reprogram the cells into a pluripotent state, which can then be specified to replicate PMOS-like traits.
=== Extrapituitary === Extrapituitary prolactin is controlled by a superdistal promoter, located 5.8 kb upstream of the pituitary start site. The promoter does not react to dopamine, estrogens, or TRH. Instead, it is stimulated by cAMP. Responsiveness to cAMP is mediated by an imperfect cAMP–responsive element and two CAAT/enhancer binding proteins (C/EBP). Progesterone upregulates prolactin synthesis in the endometrium but decreases it in myometrium and breast glandular tissue. Breast and other tissues may express the Pit-1 promoter in addition to the distal promoter. Oct-1 appears able to substitute for Pit-1 in activating the promoter in breast cancer cells. Extrapituitary production of prolactin is thought to be special to humans and primates and may serve mostly tissue-specific paracrine and autocrine purposes. It has been hypothesized that in vertebrates such as mice a similar tissue-specific effect is achieved by a large family of prolactin-like proteins controlled by at least 26 paralogous PRL genes not present in primates.
== Side effects == Eosinophilia is a known side effect of dupilumab. Injection site reactions such as redness and pain are common, occurring in approximately 11.4% of cases. Dupilumab can cause allergic reactions, conjunctivitis, and keratitis and, due to its immunosuppressive effects, reactivation of cold sores. Arthralgias (joint pain) and psoriasis have also been reported as side effects.
Sources: en.wikipedia.org
There are differences in the regulation for the release of GMOs between countries, with some of the most marked differences occurring between the US and Europe. Regulation varies in a given country depending on the intended use of the products of the genetic engineering. For example, a crop not intended for food use is generally not reviewed by authorities responsible for food safety. Some nations have banned the release of GMOs or restricted their use, and others permit them with widely differing degrees of regulation. In 2016, thirty eight countries officially ban or prohibit the cultivation of GMOs and nine (Algeria, Bhutan, Kenya, Kyrgyzstan, Madagascar, Peru, Russia, Venezuela and Zimbabwe) ban their importation. Most countries that do not allow GMO cultivation do permit research using GMOs. Despite regulation, illegal releases have sometimes occurred, due to weakness of enforcement. The European Union (EU) differentiates between approval for cultivation within the EU and approval for import and processing. While only a few GMOs have been approved for cultivation in the EU a number of GMOs have been approved for import and processing. The cultivation of GMOs has triggered a debate about the market for GMOs in Europe. Depending on the coexistence regulations, incentives for cultivation of GM crops differ. The US policy does not focus on the process as much as other countries, looks at verifiable scientific risks and uses the concept of substantial equivalence. Whether gene edited organisms should be regulated the same as genetically modified organism is debated.
==== Micronutrient undernutrition ==== Micronutrient undernutrition results from insufficient intake of vitamins and minerals. Worldwide, deficiencies in iodine, Vitamin A, and iron are the most common. Children and pregnant women in low-income countries are at especially high risk for micronutrient deficiencies. Anemia is most commonly caused by iron deficiency, but can also result from other micronutrient deficiencies and diseases. Vitamin B12 deficiency may cause anemia, but not in all cases, in which may result in changes in consciousness or thinking, or even irreversible neurological damage. This condition can have major health consequences. It is possible to have overnutrition simultaneously with micronutrient deficiencies; this condition is termed the double burden of malnutrition.
=== EC 1.17.1 With NAD or NADP as acceptor === EC 1.17.1.1: CDP-4-dehydro-6-deoxyglucose reductase EC 1.17.1.2: now classified as EC 1.17.7.4, 4-hydroxy-3-methylbut-2-enyl diphosphate reductase EC 1.17.1.3: leucoanthocyanidin reductase EC 1.17.1.4: xanthine dehydrogenase EC 1.17.1.5: nicotinate dehydrogenase EC 1.17.1.6: Now EC 1.17.99.5, bile-acid 7α-dehydroxylase. It is now known that FAD is the acceptor and not NAD+ as was thought previously EC 1.17.1.7: Now EC 1.2.1.91, 3-oxo-5,6-dehydrosuberyl-CoA semialdehyde dehydrogenase EC 1.17.1.8: 4-hydroxy-tetrahydrodipicolinate reductase EC 1.17.1.9: formate dehydrogenase EC 1.17.1.10: formate dehydrogenase (NADP+) EC 1.17.1.11: formate dehydrogenase (NAD+, ferredoxin)
=== Classification === Malignant peripheral nerve sheath tumors are a rare type of cancer that arise from the soft tissue that surrounds nerves. They are a type of sarcoma. Most malignant peripheral nerve sheath tumors arise from the nerve plexuses that distribute nerves into the limbs—the brachial and lumbar plexuses—or from nerves as they arise from the trunk.
Mitoquinone mesylate (MitoQ) is a synthetic analogue of coenzyme Q10 which has antioxidant effects. It was first developed in New Zealand in the late 1990s. It has significantly improved bioavailability and improved mitochondrial penetration compared to coenzyme Q10, and has shown potential in a number of medical indications, being widely sold as a dietary supplement. A 2014 review found insufficient evidence for the use of mitoquinone mesylate in Parkinson's disease and other movement disorders. A 2025 British study found that diabetes patients who took daily mitoquinone, a widely available antioxidant, as well as their standard treatment had healthier hearts after four months than those not given the supplement. Mitoquinone was able to reverse the early signs of diabetes-related heart failure over the course of the study.
Sources: en.wikipedia.org
Level instrumentation determines the height of liquids by measuring the position of a gas/liquid or liquid/liquid interface within the vessel or tank. Such interfaces include oil/gas, oil/water, condensate/water, glycol/condensate, etc. Local indication (LI) includes sight glasses which show the liquid level directly through a vertical glass tube attached to the vessel/tank. Phase interfaces are maintained at a constant level by level transmitters (LT) transmitting a signal to a level controller (LIC) which compares the measured value with the desired set point. The difference is sent as a signal to a level control valve (LCV) on the liquid outlet from the vessel. As the level rises the controller acts to open the valve to draw off liquid to reduce the level. Similarly as the levels fall the controller acts to close the LCV to reduce outflow of fluid. Some vessels store liquid until it is pumped out. The controller (LIC) acts to start and stop the pump within a specified band. For example, it may start the pump when the level rises to 0.6 m and stop the pump when the level falls to 0.4 m. High and low level alarms (LAH and LAL) warn operating personnel that levels are outside predefined limits. Further deviation (LAHH and LALL) initiates a shutdown either to close emergency shutdown valves (ESDV) on the inlet to the vessel or on the liquid outlet lines. As with high and low pressure instrumentation the shutdown function comprises an independent measurement loop to prevent a common mode failure.
It is responsible for the removal of interstitial fluid from tissues It absorbs and transports fatty acids and fats as chyle from the digestive system It transports white blood cells to and from the lymph nodes into the bones The lymph transports antigen-presenting cells, such as dendritic cells, to the lymph nodes where an immune response is stimulated.
=== Recreational use === Zolpidem has potential for medical misuse when the drug is continued long term without or against medical advice, or for recreational use when the drug is taken to achieve a "high". The transition from medical use of zolpidem to high-dose addiction or drug dependence can occur with use, but some believe it may be more likely when used without a clinical recommendation to continue using it, when physiological drug tolerance leads to higher doses than the usual 5 mg or 10 mg, when consumed through insufflation or injection, or when taken for purposes other than as a sleep aid. Recreational use is more prevalent in those having been dependent on other drugs in the past, but tolerance and drug dependence can still sometimes occur in those without a history of drug dependence. Chronic users of high doses are more likely to develop physical dependence on the drug, which may cause severe withdrawal symptoms, including seizures if abrupt withdrawal from zolpidem occurs. Other drugs, including benzodiazepines and zopiclone, are also found in high numbers of suspected drugged drivers. Many drivers have blood levels far exceeding the therapeutic dose range, suggesting a high degree of excessive-use potential for benzodiazepines, zolpidem, and zopiclone. U.S. Congressman Patrick J. Kennedy says that he was using zolpidem (Ambien) and promethazine (Phenergan) when he was caught driving erratically at 3 a.m. "I simply do not remember getting out of bed, being pulled over by the police, or being cited for three driving infractions," Kennedy said.
=== 2011–2012: Early career === Hibberd was drafted by the Essendon Football Club with their only selection and fourth overall in the 2011 pre-season draft. He made his AFL debut in the 139-point win against Gold Coast at Etihad Stadium in round six. He was omitted the next week for the match against West Coast, before returning in round eight in the thirty-six point win against Brisbane at the Gabba, where he recorded twenty-two disposals and was praised by then-Essendon coach, James Hird, in particular for his courage around the ball. Playing the next seven matches, he missed the round seventeen match against Adelaide at AAMI Stadium due to a hamstring injury. After playing the first five matches for the 2012 season, he suffered a hamstring injury during the first quarter of the Anzac Day clash against Collingwood in round five, which forced him to miss six weeks of football. He made his return from injury through the Victorian Football League (VFL), playing for Essendon's affiliate team, Bendigo. After playing two matches in the VFL, he returned to the AFL side for the twenty-four point win against Fremantle at Patersons Stadium in round thirteen. He played the next three matches before injuring his quad in the fifty point win against Port Adelaide at AAMI Stadium in round sixteen. He missed three weeks due to the injury and returned to the side for the twenty-four point loss against North Melbourne at Etihad Stadium in round twenty.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.